17 Although in both studies, SLE Responder Index (SRI)-4 responses at 52 weeks were higher with belimumab versus placebo, the EMBRACE did not reach statistical significance (SRI response at week 52 48.7% with belimumab versus 41.6% with placebo (OR 1.40, 95% CI 0.93 to 2.11)).
← all excerpts
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
1
—
—